Begrüßungen Dr. Julia Wagle
Prof. Dr. Stefan Endres
10:35 - 10:50
Introduction:
Engineering therapeutic antibodies PD Dr. Christian Klein, Schlieren
Bispecifics I
11:00 – 11:20
Kaffeepause
11:20 – 11:35
T cell engaging bispecific antibodies: blinatumomab and beyond Prof. Ralf Bargou Direktor des Comprehensive Cancer Center Mainfranken
Lehrstuhlinhaber für Translationale Onkologie Uniklinikum Würzburg
11:45 – 12:00
Targeting and exploiting onco-fetal tolerance mechanisms for cancer and autoimmunity Prof. Dr. Jörg Wischhusen,
Universitätsklinikum Würzburg
12:10 – 12:25
Biomedical potential of bi- and multifunctional immunocytokines Prof. Dr. Stefan Zielonka,
Global Head of Antibody Discovery & Protein Engineering (ADPE)
Research & Development, Merck Healthcare KGaA, Darmstadt,
Technische Universität Darmstadt
12:35 – 13:35
Mittagessen
Bispecifics II
13:35 – 13:50
IgA as alternative isotype to treat cancer Prof. Dr. Jeanette Leusen,
UMC Utrecht
14:00 – 14:15
Multifunctional fusion proteins for the targeted activation and expansion of immune effector cells Prof. Dr. Matthias Peipp,
Medizinische Klinik II, Sektion für Stammzell- und Immuntherapie Universitätsklinikum Schleswig-Holstein, Kiel
14:25 – 14:40
T Cell Engaging Receptors (TCER): Next- generation, half-life-extended bispecifics targeting HLA-bound peptides Dr. Meike Hutt,
Immatics Biotechnologies GmbH
14:50 – 15:05
Breaking new ground in ophthalmology: A gene therapy development for in vivo generation of antibodies Dr. Mathias Schifflers,
Global Medical Affairs Eyecare AbbVie Deutschland GmbH & Co. KG, Ludwigshafen
15:15 – 15:45
Kaffeepause
Payloads
15:45 – 16:00
Maximizing payload delivery of antibody-drug conjugates (ADCs) to tumors through a novel linker technology Dr. Philipp Spycher,
CSO Araris Biotech AG, Zürich
16:10 – 16:25
Targeted radionuclide therapy:
How the targeting moiety can impact clinical outcome Prof. Dr. Theresa Kolben,
Global Head Early Clinical Development Oncology, Bayer AG
16:35 – 16:50
Designed Ankyrin Repeat Protein (DARPin)- based therapies and gene therapy-based in vivo antibody delivery Prof. Dr. Andreas Plückthun,
Biochemisches Institut Universität Zürich, Zürich
